108
Participants
Start Date
November 30, 2008
Primary Completion Date
March 31, 2017
Study Completion Date
March 31, 2017
Brivaracetam
Subjects will begin at a recommended dose of Brivaracetam 100 mg/day. Subjects will continue treatment at a dose up to a maximum of 200 mg/day with a twice per day administration. Up- and down-titration steps may be performed in steps of a maximum of 50 mg/day on a weekly basis. Full down-titration should include a one week step on 20 mg/day. The study medication will come in 10 mg and 25 mg tablet strengths.
304, Phoenix
281, Fresno
288, Pasadena
240, Riverside
245, Sacramento
285, Peoria
224, Indianapolis
266, Lexington
231, Waldorf
278, Burlington
270, New York
284, Hickory
241, Columbus
265, Oklahoma City
297, Germantown
260, Austin
236, Bedford
267, Dallas
268, Houston
211, Layton
235, Ogden
218, Burlington
279, Danville
277, Charleston
213, Marshfield
400, Chatswood
404, Adelaide
402, Fitzroy
401, Parkville
004, Ghent
003, Kortrijk
205, Calgary
203, Edmonton
206, Toronto
023, Brno
020, Litomyšl
021, Ostava
024, Ostrava-Trebovice
026, Prague
040, Béthune
041, Toulouse
055, Berlin
056, Bernau
054, Bielefeld
063, Mainz
051, München
065, Regensburg
072, Budapest
074, Budapest
084, Bergamo
082, Messina
085, Orbassano
083, Perugia
080, Pisa
090, Madrid
100, Gothenburg
102, Lund
101, Stockholm
Lead Sponsor
UCB Pharma
INDUSTRY